Antibody purification and purity monitoring
View Patent ↗Processes for producing and purifying recombinant proteins are disclosed. In particular, the present disclosure provides processes of producing and purifying multi-subunit proteins expressed in yeast or filamentous fungal cells. The production and/or purification of such proteins are monitored for impurities, preferably using lectin binding assays, such that one or more process parameters may be adjusted to maximize the amount of desired recombinant protein and minimize the amount of glycosylated impurities. The processes can also be monitored for other undesired product-associated impurities, such as aggregates and nucleic acids. In exemplary embodiments, the recombinant proteins are multi-subunit proteins, such as antibodies, the host cell is a yeast, such as Pichia pastoris , and the glycosylated impurity is a glycovariant of the desired recombinant polypeptide, such as an N-linked and/or O-linked glycovariant.
1. A fermentation process for producing a desired recombinant antibody polypeptide and purifying the desired recombinant polypeptide from the fermentation medium, wherein the process includes:
(i) conducting one or more fermentation processes or runs which each comprise culturing yeast cells under conditions that result in the expression and secretion of a desired recombinant polypeptide and one or more impurities into the fermentation medium;
(ii) periodically obtaining one or more samples of the fermentation medium as each fermentation process proceeds or after different fermentation runs are conducted;
(iii) detecting the amount and/or type of glycosylated impurities in the sample(s) using a lectin that binds to said glycosylated impurities, and
(iv) modifying one or more of the operating parameters or conditions of one or more of the fermentation processes or runs based on the amount of detected glycosylated impurities in the sample(s), wherein said operating parameters or conditions are selected from the group consisting of temperature, pH, gas constituent, feed constituent, agitation, aeration, antifoam and duration, while said fermentation processes or runs are being conducted, and
(v) pooling different samples, eluates or fractions thereof containing the desired recombinant antibody polypeptide from the same or different fermentation processes or runs as the fermentation processes or runs are being conducted based on the amount and/or type of detected glycosylated impurity relative to the amount of the recombinant antibody polypeptide in said different samples, eluates or fractions thereof.
2. The process of claim 1 , wherein
(i) the impurities are the result of O-linked glycosylation,
(ii) the detection step is effected using at least one lectin selected from ConA, LCH, GNA or GNL, RCA, DC-SIGN, L-SIGN, PNA, AIL, VVL, WGA, SNA, MAL, MAH, UEA and AAL, and/or at least one lectin selected from PNA, SBA, PWM, PEA, PTA, ML-I-III, LEA, UDA, WGA, PHA, LTA, BSI-B4, MPA, RCA, LCA, ECA, AAA, DBA, GSL-I, PSA, SJA, DSL, ECL, GSL-II, AIA/Jacalin, LEL, STL, HHL, LCA, NPL, ACL, ECL, EEL, MAL-I, AAL, LTL, BPL, MPL, PTL, SNA, DGL, SJA, VVA, LEA, STA, DSA, MMR, DEC-205, Dectin 1, Dectin 2, Langerin, or BDCA-2, which optionally may be bound to a support,
(iii) the detection step uses a protein-protein interaction monitoring process, wherein the protein-protein interaction monitoring process uses light interferometry, dual polarization interferometry, static light scattering, dynamic light scattering, multi-angle light scattering, surface plasmon resonance , ELISA, chemiluminescent ELISA, far western, or electroluminescence or any combination of (i)-(v).
3. The process of claim 1 , wherein said operating parameters or conditions are selected from at least two of said operating parameters or conditions.
4. The process of claim 1 , wherein the glycosylated impurity is a glycovariant of the recombinant polypeptide and the recombinant polypeptide is an antibody or antibody fragment.
5. The process of claim 1 , wherein the host cell is a Pichia pastoris , which expresses an antibody or antibody fragment.
6. The process of claim 1 , which further includes recovering or purifying the recombinant polypeptide from the fermentation medium.
7. The process of claim 6 , wherein the purification process further comprises:
(i) contacting the sample(s) with at least one chromatographic support and selectively eluting the desired recombinant polypeptide,
(ii) pooling different samples or eluates or fractions thereof containing a desired recombinant antibody based on the amount and/or type of detected glycosylated impurity,
(iii) pooling different samples or eluates or fractions thereof containing the desired recombinant antibody based on the amount and/or type of detected glycosylated impurity relative to the amount of recombinant antibody, or any combination of the foregoing (i)-(ii).
8. The process of claim 6 , further comprising detecting the amount of aggregated and/or disaggregated impurities in said sample(s) of step (iii) using size exclusion chromatography and modifying one or more of the operating parameters or conditions of one or more of the fermentation processes or run, wherein said operating parameters or conditions are selected from temperature, pH, gas constituent, feed constituent, agitation, aeration, antifoam and duration.
9. The process of claim 6 , wherein the recombinant polypeptide is an antibody or antibody fragment which is monovalent, bivalent or multivalent.
10. The process of claim 6 , wherein said antibody or antibody fragment specifically binds to IL-2, IL-4, IL-6, IL-10, IL-12, IL-13, IL-17, IL-18, IFN-alpha, IFN-gamma, BAFF, CXCL13, IP-10, CBP, angiotensin (angiotensin I and angiotensin II), Nav 1.7, Nav 1.8, VEGF, PDGF, EPO, EGF, FSH, TSH, hCG, CGRP, NGF, TNF, HGF, BMP2, BMP7, PCSK9 or HRG.
11. The process of claim 1 , wherein said glycosylated impurity in step (v) is selected from the group consisting of (i) samples or eluate or fractions thereof comprising less than 10% glycovariant, (ii) samples or eluate or fractions thereof comprising less than 5% glycovariant, (iii) samples or eluate or fractions thereof comprising less than 1% glycovariant and (iv) samples or eluate or fractions thereof comprising less than 0.5% glycovariant.